Steven M. Horwitz, MD, on SYK/JAK Inhibitor Treatment for T-Cell Lymphomas

Posted: Tuesday, December 4, 2018

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.